Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Beta Bionics, Inc.NASDAQ: BBNX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 5.3% from a year ago
Total current assets stood at $247.99M at the end of Q1 FY2026, down 5.3% from a year earlier and down 7.4% from the prior quarter. Over 3 fiscal years it compounded at +111.1% a year.
Context
- Total current assets amounted to 81.5% of total assets at the end of Q1 FY2026, up 4.0 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -5.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 267.91M USD
- Year-over-year change
- +101.5%
- 3-year CAGR
- +111.1%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 267.91M | +101.5% |
| FY2024 | 2024-12-31 | 132.92M | +28.3% |
| FY2023 | 2023-12-31 | 103.62M | +264.0% |
| FY2022 | 2022-12-31 | 28.47M | — |
Total Current Assets vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -5.3% is the 3rd highest of 7, against a peer median of -13.2%.
- Total current assets amounts to 81.5% of total assets for BBNX, versus a peer median of 35.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 208.7B DKK | +28.3% | +16.8% | 35.1% | |
| Jun 2026 | $4.09B USD | -18.8% | +3.2% | 63.3% | |
| Jun 2026 | $1.85B USD | -18.1% | +13.3% | 58.4% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $1.42B USD | — | — | 30.0% |
| Mar 2026 | $887.1M USD | +33.7% | -10.1% | 76.9% | |
| Mar 2026 | $251.16M USD | -8.2% | +7.5% | 33.7% | |
| Mar 2026 | $247.99M USD | -5.3% | +111.1% | 81.5% | |
| Mar 2026 | $68.15M USD | -48.2% | -5.3% | 25.3% | |
| Peer median (excluding BBNX) | — | -13.2% | +5.3% | 35.1% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.